INVIVYD, INC. Stock-Based Compensation
INVIVYD, INC. (IVVD) reported Stock-Based Compensation of $5.59 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-13
- INVIVYD, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $2.90M, a 8.96% decline year-over-year.
- INVIVYD, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $2.70M, a 4.56% decline year-over-year.
- INVIVYD, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $2.56M, a 16.13% decline year-over-year.
- INVIVYD, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $3.07M, a 7.33% increase year-over-year.
- INVIVYD, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $11.64M, a 41.16% decline from fiscal 2024.
- INVIVYD, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $19.79M, a 5.90% increase from fiscal 2023.
- INVIVYD, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $18.68M, a 13.69% decline from fiscal 2022.
- INVIVYD, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $21.65M.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 4 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 7 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $5.59M 10-Q · filed 2026-08-13 | $8.16M derived: sum of 3 quarters · filed 2026-08-13 | $11.23M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $2.70M 10-Q · filed 2026-05-14 | $5.26M derived: sum of 2 quarters · filed 2026-05-14 | $8.33M derived: sum of 3 quarters · filed 2026-05-14 | $11.51M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-12-31 | $2.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $5.64M derived: sum of 2 quarters · filed 2026-03-05 | $8.82M derived: sum of 3 quarters · filed 2026-08-13 | $11.64M 10-K · filed 2026-03-05 | ||
| 2025-09-30 | $3.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $6.25M derived: sum of 2 quarters · filed 2026-08-13 | $9.08M 10-Q · filed 2025-11-06 | $12.14M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-06-30 | $3.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $6.01M 10-Q · filed 2026-08-13 | $9.06M derived: sum of 3 quarters · filed 2026-08-13 | $11.93M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $2.83M 10-Q · filed 2026-05-14 | $5.88M derived: sum of 2 quarters · filed 2026-05-14 | $8.75M derived: sum of 3 quarters · filed 2026-05-14 | $17.23M derived: sum of 4 quarters · filed 2026-05-14 | ||
| 2024-12-31 | $3.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $5.92M derived: sum of 2 quarters · filed 2026-03-05 | $14.41M derived: sum of 3 quarters · filed 2026-03-05 | $19.79M 10-K · filed 2026-03-05 | ||
| 2024-09-30 | $2.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $11.35M derived: sum of 2 quarters · filed 2025-11-06 | $16.73M 10-Q · filed 2025-11-06 | $21.07M derived: sum of 4 quarters · filed 2025-11-06 | ||
| 2024-06-30 | $8.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $13.87M 10-Q · filed 2025-08-14 | $18.21M derived: sum of 3 quarters · filed 2025-08-14 | $22.48M derived: sum of 4 quarters · filed 2025-08-14 | ||
| 2024-03-31 | $5.38M 10-Q · filed 2025-05-15 | $9.72M derived: sum of 2 quarters · filed 2025-05-15 | $13.99M derived: sum of 3 quarters · filed 2025-05-15 | $18.66M derived: sum of 4 quarters · filed 2025-05-15 | ||
| 2023-12-31 | $4.34M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $8.61M derived: sum of 2 quarters · filed 2025-03-20 | $13.29M derived: sum of 3 quarters · filed 2025-03-20 | $18.68M 10-K · filed 2025-03-20 | ||
| 2023-09-30 | $4.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $8.94M derived: sum of 2 quarters · filed 2024-11-14 | $14.34M 10-Q · filed 2024-11-14 | $20.25M derived: sum of 4 quarters · filed 2024-11-14 | ||
| 2023-06-30 | $4.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $10.08M 10-Q · filed 2024-08-14 | $15.98M derived: sum of 3 quarters · filed 2024-08-14 | $23.38M derived: sum of 4 quarters · filed 2024-08-14 | ||
| 2023-03-31 | $5.40M 10-Q · filed 2024-05-09 | $11.30M derived: sum of 2 quarters · filed 2024-05-09 | $18.70M derived: sum of 3 quarters · filed 2024-05-09 | $25.07M derived: sum of 4 quarters · filed 2024-05-09 | ||
| 2022-12-31 | $5.91M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $13.30M derived: sum of 2 quarters · filed 2024-03-28 | $19.66M derived: sum of 3 quarters · filed 2024-03-28 | $21.65M 10-K · filed 2024-03-28 | ||
| 2022-09-30 | $7.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $13.76M derived: sum of 2 quarters · filed 2023-11-09 | $15.74M 10-Q · filed 2023-11-09 | $23.60M derived: sum of 4 quarters · filed 2024-02-09 | ||
| 2022-06-30 | $6.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $8.34M 10-Q · filed 2023-08-10 | $16.20M derived: sum of 3 quarters · filed 2024-02-09 | $22.18M derived: sum of 4 quarters · filed 2024-02-09 | ||
| 2022-03-31 | $1.98M 10-Q · filed 2023-05-11 | $9.84M derived: sum of 2 quarters · filed 2024-02-09 | $15.82M derived: sum of 3 quarters · filed 2024-02-09 | $19.16M derived: sum of 4 quarters · filed 2024-02-09 | ||
| 2021-12-31 | $7.86M derived: 8-K 12 month − 10-Q 9 month · filed 2024-02-09 | $13.84M derived: sum of 2 quarters · filed 2024-02-09 | $17.18M derived: sum of 3 quarters · filed 2024-02-09 | $17.76M 8-K · filed 2024-02-09 | ||
| 2021-09-30 | $5.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $9.32M derived: sum of 2 quarters · filed 2022-11-10 | $9.91M 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | $3.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $3.93M 10-Q · filed 2022-08-15 | ||||
| 2021-03-31 | $587.00K 10-Q · filed 2022-05-13 | |||||
| 2020-12-31 | $155.00K 10-K · filed 2022-03-31 | |||||
| 2020-09-30 | $7.00K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |